{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is IMAC Holdings, Inc. overvalued or undervalued?
As of February 10, 2025, IMAC Holdings, Inc. is considered overvalued with a negative price-to-book value and an EV to EBITDA ratio indicating insufficient earnings, while its stock has plummeted 97.59% over the past year, contrasting sharply with its peers and the overall market.
Is IMAC Holdings, Inc. technically bullish or bearish?
As of May 27, 2025, IMAC Holdings, Inc. shows a mildly bearish trend overall, with daily moving averages indicating bearishness, while weekly MACD and RSI suggest short-term bullish momentum, leading to a cautious investment approach.
What does IMAC Holdings, Inc. do?
IMAC Holdings, Inc. provides movement and orthopedic therapies and minimally invasive procedures in the Pharmaceuticals & Biotechnology sector. It has a market cap of $0.17 million and reported a net profit loss of $2 million as of December 2024.
How big is IMAC Holdings, Inc.?
As of Jun 18, IMAC Holdings, Inc. has a market capitalization of 0.17 million, categorizing it as a Micro Cap company, with recent net sales of 0.08 million and a net profit of -6.29 million over the last four quarters. Shareholder's funds are -6.39 million, and total assets are valued at 1.59 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
